LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$3.4M
Cash & Equivalents
$1.8M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$125M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT03886662 A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) PHASE2 Recruiting 47

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for LIXT.

SEC EDGAR Filings

All SEC filings for LIXTE BIOTECHNOLOGY HOLDINGS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.